These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

259 related items for PubMed ID: 28481727

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Characteristics of veterans receiving buprenorphine vs. methadone for opioid use disorder nationally in the Veterans Health Administration.
    Manhapra A, Quinones L, Rosenheck R.
    Drug Alcohol Depend; 2016 Mar 01; 160():82-9. PubMed ID: 26804898
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.
    Seal KH, Maguen S, Bertenthal D, Batki SL, Striebel J, Stein MB, Madden E, Neylan TC.
    J Clin Psychiatry; 2016 Sep 01; 77(9):1182-1188. PubMed ID: 27035058
    [Abstract] [Full Text] [Related]

  • 5. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients.
    Finlay AK, Harris AH, Rosenthal J, Blue-Howells J, Clark S, McGuire J, Timko C, Frayne SM, Smelson D, Oliva E, Binswanger I.
    Drug Alcohol Depend; 2016 Mar 01; 160():222-6. PubMed ID: 26832998
    [Abstract] [Full Text] [Related]

  • 6. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
    Lin LA, Bohnert ASB, Blow FC, Gordon AJ, Ignacio RV, Kim HM, Ilgen MA.
    Addiction; 2021 Jan 01; 116(1):96-104. PubMed ID: 32428386
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
    Manhapra A, Stefanovics E, Rosenheck R.
    Subst Abus; 2020 Jan 01; 41(1):110-120. PubMed ID: 31403914
    [Abstract] [Full Text] [Related]

  • 15. Association of mental health disorders with prescription opioids and high-risk opioid use in US veterans of Iraq and Afghanistan.
    Seal KH, Shi Y, Cohen G, Cohen BE, Maguen S, Krebs EE, Neylan TC.
    JAMA; 2012 Mar 07; 307(9):940-7. PubMed ID: 22396516
    [Abstract] [Full Text] [Related]

  • 16. Barriers and Facilitators to Implementation of Pharmacotherapy for Opioid Use Disorders in VHA Residential Treatment Programs.
    Finlay AK, Wong JJ, Ellerbe LS, Rubinsky A, Gupta S, Bowe TR, Schmidt EM, Timko C, Burden JL, Harris AHS.
    J Stud Alcohol Drugs; 2018 Nov 07; 79(6):909-917. PubMed ID: 30573022
    [Abstract] [Full Text] [Related]

  • 17. Use of naltrexone in treating opioid use disorder in pregnancy.
    Towers CV, Katz E, Weitz B, Visconti K.
    Am J Obstet Gynecol; 2020 Jan 07; 222(1):83.e1-83.e8. PubMed ID: 31376396
    [Abstract] [Full Text] [Related]

  • 18. Characteristics and current clinical practices of opioid treatment programs in the United States.
    Jones CM, Byrd DJ, Clarke TJ, Campbell TB, Ohuoha C, McCance-Katz EF.
    Drug Alcohol Depend; 2019 Dec 01; 205():107616. PubMed ID: 31678836
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.